Key points from article :
Taisho Pharmaceutical and Insilico Medicine have entered into collaboration to identify novel therapeutics against aging.
Insilico Medicine will use both the target discovery and generative chemistry parts of its Pharma.AI platform.
Taisho has already developed the HIF-PH inhibitor recently licensed by BioAge.
"AI-powered drug discovery suites together with Taisho’s to explore the new space of anti-aging solutions.”- Jimmy Yen-Chu Lin, CEO of Insilico Medicine.
Insilico Medicine will be responsible for early research phase target identification and molecular generation.
Taisho will work collaboratively with Insilico in validating the results in various in vitro and in vivo assays.
“The high level of scientists, and our previous successes, experience in senolytic drug discovery give us confidence that this collaboration will be successful,” Alex Zhavoronkov, founder and CEO of Insilico Medicine.
